{
    "Rank": 1052,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT05589558",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "Sechenov-four_biopsies"
                },
                "Organization": {
                    "OrgFullName": "I.M. Sechenov First Moscow State Medical University",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection",
                "OfficialTitle": "Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2022",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 1, 2020",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "February 25, 2022",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 25, 2022",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 18, 2022",
                "StudyFirstSubmitQCDate": "October 18, 2022",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 21, 2022",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "October 18, 2022",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 21, 2022",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Dmitry Enikeev, MD, PhD",
                    "ResponsiblePartyInvestigatorTitle": "Professor",
                    "ResponsiblePartyInvestigatorAffiliation": "Medical University of Vienna"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "I.M. Sechenov First Moscow State Medical University",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No",
                "IsUSExport": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "The aim of this study is to compare clinically significant prostate cancer detection rate by the 4 biopsy methods: TRUS-guided, cognitive, fusion and transperineal template mapping biopsy.\n\nIt is recommended to combine MRI-guided biopsy with systematic (TRUS-guided or transperineal template mapping biopsy) biopsy for high yield of prostate cancer diagnosis. Nevertheless, it remains unclear which biopsy combination is more precise for prostate cancer detection.",
                "DetailedDescription": "Taking into consideration the variety of prostate biopsy methods (TRUS-guided, cognitive, fusion and transperineal template mapping biopsy), the issue of indications for each of them remains unresolved. Current EAU guidelines recommend combining MRI-guided biopsy with systematic (TRUS-guided or transperineal template mapping biopsy) one for high yield of prostate cancer diagnosis. Nevertheless, it also remains unclear which biopsy combination is more precise for prostate cancer detection.\n\nThis is a prospective single-arm study.\n\nAll patients underwent prostate TRUS examination and mpMRI. Suspicious lesion found on MRI were classified with the Pi-RADS v2.1. First step: the \"unblinded\" urologist \u21161 performed a fusion and transperineal template mapping biopsy. Second step: the \"blinded\" urologist \u21162 performed TRUS-guided and cognitive biopsy.\n\nObjectives of the study: to determine clinically significant prostate cancer detection rate, overall cancer detection rate, clinically insignificant prostate cancer detection rate, sampling efficiency (positive biopsy cores' number, maximum cancer core length (MCCL)). Results were calculated for each biopsy method separately and for combinations of TRUS-guided and cognitive biopsy (combination \u21161) and fusion and transperineal template mapping biopsy (combination \u21162)."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer",
                        "Prostate Adenocarcinoma"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "prostate cancer",
                        "fusion biopsy",
                        "cognitive biopsy",
                        "transrectal ultrasound biopsy",
                        "transperineal template mapping biopsy"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignInterventionModelDescription": "First step: the \"unblinded\" urologist \u21161 performed a fusion and transpeineal template mapping biopsy. Second step: the \"blinded\" urologist \u21162 performed TRUS-guided and cognitive biopsy. All specimens were obtained within a single procedure.",
                    "DesignPrimaryPurpose": "Diagnostic",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)",
                        "DesignMaskingDescription": "The \"blinded\" urologist performed TRUS-guided and cognitive biopsy without prior knowledge about MRI results"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "102",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Patients with suspected prostate cancer underwent 4 biopsy methods",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients with suspected prostate cancer consequently underwent TRUS-guided, cognitive, fusion and transperineal template mapping biopsy",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)",
                            "InterventionDescription": "TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Patients with suspected prostate cancer underwent 4 biopsy methods"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Clinically significant prostate cancer detection rate",
                            "PrimaryOutcomeDescription": "Ratio of patients with preoperative Pi-RADS \u22653 with defined clinically significant prostate cancer (ISUP \u22652) in relation to total number of patients",
                            "PrimaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Overall prostate cancer detection rate",
                            "SecondaryOutcomeDescription": "Ratio of patients with preoperative Pi-RADS \u22653 with defined prostate cancer in relation to total number of patients",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Clinically insignificant prostate cancer detection rate",
                            "SecondaryOutcomeDescription": "Ratio of patients with preoperative Pi-RADS \u22653 with defined clinically insignificant prostate cancer (ISUP 1) in relation to total number of patients",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Positive biopsy cores' number",
                            "SecondaryOutcomeDescription": "Ratio of cores with detected prostate cancer in relation to overall numbers of cores",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Maximum cancer core length",
                            "SecondaryOutcomeDescription": "Median length of core with prostate cancer in realtion to whole biopsy core",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Number of missed clinically significant prostate cancer",
                            "SecondaryOutcomeDescription": "Ratio of patients with preoperative Pi-RADS \u22653 with downgraded ISUP score in relation to maximum ISUP score obtained among biopsies",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Added value of prostate cancer",
                            "SecondaryOutcomeDescription": "Ratio of patients with preoperative Pi-RADS \u22653 with upgraded ISUP score in relation to maximum ISUP score obtained among biopsies",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Predicting factors of PCa detection",
                            "SecondaryOutcomeDescription": "Prognostic factors of clinically significant and overall prostate cancer detection rate",
                            "SecondaryOutcomeTimeFrame": "2 weeks after performed 4 biopsy methods"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Comparison of biopsies and post-prostatectomy pathological results",
                            "SecondaryOutcomeDescription": "Gleason score obtained within biopsy and the post-prostatectomy pathology",
                            "SecondaryOutcomeTimeFrame": "2 weeks after radical prostatectomy"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPSA >2 ng/mL, and/or positive digital rectal examination (DRE), and/or suspicious lesion on TRUS\nPi-RADSv2.1 \u22653 score\n\nExclusion Criteria:\n\npreviously diagnosed PCa;\nacute prostatitis within the last 3 months;\n5-\u03b1 reductase inhibitors therapy within the last 6 months;\nextracapsular extension;\nprostate volume \u226580 cc;\ncontraindications for mpMRI.",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Institute for Urology and Reproductive Health, Sechenov University.",
                            "LocationCity": "Moscow",
                            "LocationZip": "119991",
                            "LocationCountry": "Russian Federation"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "33172724",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouviere O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7."
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M3275",
                            "ConditionBrowseLeafName": "Adenocarcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}